Terbium-161 labelling of glycoproteins PSMA and monoclonal antibodies

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21340%2F24%3A00378183" target="_blank" >RIV/68407700:21340/24:00378183 - isvavai.cz</a>

Result on the web

<a href="https://events.ncbj.gov.pl/event/322/attachments/601/976/Book_of_abstracts.pdf" target="_blank" >https://events.ncbj.gov.pl/event/322/attachments/601/976/Book_of_abstracts.pdf</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Terbium-161 labelling of glycoproteins PSMA and monoclonal antibodies

Original language description

Terbium-161, as a perspective radionuclide, produced in our institute, was used for labelling of prostate-specific membrane antigen (PSMA) beside the investigation of labelling conditions of selected monoclonal antibodies (MABs) rituximab and bevacizumab. The objective of the first part research task was to prepare radiopharmaceuticals 161Tb-PSMA-617 and 161Tb-PSMA I&T in high abundance and specific activity, to study their stability in biological matrices and in a mouse model. Both radioligands were prepared with yields over 99% and demonstrate sufficient stability in 48 hours post reaction. It was demonstrated high uptake in tumors of both PSMA ligands on LNCaP cell lines in vivo, while 161Tb-PSMA I&T exibit slower clearence and higher retention in lungs and heart. Labelling of MABs was studied on an antibody targeting the vascular endothelial factor (VEGF) angiogenesis-stimulating bevacizumab and the anti-CD20-rituximab targeting conjugate. Both conjugates were prepared by conjugating antibodies with DOTA-NHS. Yields were approximately 20% in both cases. The labeled bevacizumab conjugate was separated from free Tb-161 and applied to a mouse model of the SKOV3 tumor line. After 7 days from the application, most of the antibody was taken up in the tumor tissue. On both models we proved, that Tb-161 produced on LVR-15 meet the criteria for labelling and radioconjugates reveals stability and significant tumor uptake in vivo.

Czech name

—

Czech description

—

Type

O - Miscellaneous

CEP classification

—

OECD FORD branch

10402 - Inorganic and nuclear chemistry

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů